Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Rowland

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2007
Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolationAndrew Rowland, Paraskevi Gaganis, David J Elliot, et al.
The AAPS Journal|January 6, 2021
Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine ExposureSarah Badaoui, Ashley M Hopkins, A David Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Elizabeth Garrett-Mayer, et al.
JAMA Oncology|December 27, 2019
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung CancerGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
Journal of Hypertension|June 2, 2021
Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomesGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Multiorgan Immune-Related Adverse Events During Treatment With AtezolizumabGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2015
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver MicrosomesKushari Burns, Pramod C Nair, Andrew Rowland, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 1, 2015
Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human diseaseMadelé van Dyk, Arduino A Mangoni, Mark McEvoy, et al.
Cancers|April 30, 2021
Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial CancerAhmad Y Abuhelwa, Ganessan Kichenadasse, Ross A McKinnon, et al.
Cancers|August 7, 2021
Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176"Ashley M Hopkins, Ganessan Kichenadasse, Ahmad Y Abuhelwa, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2007
Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolationAndrew Rowland, Paraskevi Gaganis, David J Elliot, et al.
The AAPS Journal|January 6, 2021
Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine ExposureSarah Badaoui, Ashley M Hopkins, A David Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor AtezolizumabAshley M Hopkins, Ganessan Kichenadasse, Elizabeth Garrett-Mayer, et al.
JAMA Oncology|December 27, 2019
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung CancerGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
Journal of Hypertension|June 2, 2021
Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomesGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Multiorgan Immune-Related Adverse Events During Treatment With AtezolizumabGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2015
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver MicrosomesKushari Burns, Pramod C Nair, Andrew Rowland, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 1, 2015
Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human diseaseMadelé van Dyk, Arduino A Mangoni, Mark McEvoy, et al.
Cancers|April 30, 2021
Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial CancerAhmad Y Abuhelwa, Ganessan Kichenadasse, Ross A McKinnon, et al.
Cancers|August 7, 2021
Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176"Ashley M Hopkins, Ganessan Kichenadasse, Ahmad Y Abuhelwa, et al.
Pageof 19